Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection

Hansen Chen\textsuperscript{1} *, Qiaohui Du\textsuperscript{2} *

1. Department of Neurosurgery, School of Medicine, Stanford University
2. School of Chinese Medicine, The University of Hong Kong

*These two authors contributed equally to this study

Corresponding:

Dr. Hansen Chen: chenhs@stanford.edu
Or Mr. Qiaohui Du: elvisdu@hku.hk
Abstract

SARS-CoV-2 (2019-nCoV), a novel coronavirus, caused the pneumonia outbreak in China and continue to expand. The host receptor for 2019-nCoV Angiotensin-converting enzyme 2 (ACE2), is the same as the host receptor for SARS-CoV. Targeting ACE2 holds the promise for preventing and inhibiting 2019-nCoV infection. Chinese Medicine herbs could be a valuable pool for identifying active compounds for treating infection of 2019-nCoV. In this study, we summarize several active compounds including baicalin, Scutellarin, Hesperetin, Nicotianamine and glycyrrhizin that could have potential anti-2019-nCoV effects. We conduct molecular docking to predict their capacity for binding ACE2, which may prevent the 2019-nCoV infection. We propose that these selected compounds worth further investigation for preventing 2019-nCoV.

Keywords: SARS-CoV-2 (2019-nCoV), Baicalin, Scutellarin, Hesperetin, Nicotianamine, Glycyrrhizin
Introduction

SARS-CoV-2 (2019-nCoV), a novel coronavirus, caused the pneumonia outbreak in Wuhan city, Hubei Province, China and subsequently expands. The original pneumonia cases were linked to a large seafood and animal market in Wuhan. This is an emerging, rapidly evolving situation. One genome sequence (WH-Human_1) of the 2019-nCoV was first released on Jan 10, 2020, and subsequently, five additional Wuhan CoV genome sequences were released (Zhang, 2020; Shu and McCauley, 2017). By comparing to the genomes of SARS-CoV and MERS-CoV, the WH-human_1 genome has a better sequence homology toward the genomes of SARS-CoV than that of MERS-CoV. By using structural modeling of its S-protein, scientists suggest a strong interaction of human ACE2 molecules with 2019-nCoV (Xu et al. 2020). ACE2 is a type I integral membrane protein, with its active site domain exposed to the extracellular surface of cells. ACE2 has been demonstrated to be a functional receptor for the SARS-coronavirus (CoV) (Kuhn et al., 2006). Michael Letko et al. showed that the 2019-nCoV receptor-binding domain (RBD) was capable of entering cells expressing human ACE2, but not any of the other receptors, further confirming that human ACE2 is the receptor for the recently emerging 2019-nCoV (Letko & Munster, 2020). As the host cell receptor is critical
for the virus entry, targeting ACE2 holds the promise for preventing infection of 2019-nCoV infection.

The development of drugs for targeting ACE2 and treating 2019-nCoV could be time-consuming, and the safety of newly-developed drugs could be a major concern, which needs time for testing. Therefore, it seems unrealistic to synthesize new drugs and tests for safety and toxicity within such a limited time when the infection is growing fast. Traditional Chinese Medicine has been practiced in China for thousands of years, and Chinese medicine licorice was suggested to be promising for treating SARS (Pilcher, 2003). Considering the low toxicity and availability, screening active compounds from Chinese herbal medicine for targeting the ACE2 receptor could be a potential strategy for treating 2019-nCoV. In this mini-review, we summarize the potential natural compounds that could target ACE2 for the potential treatment of 2019-nCoV. By using molecular docking, we proposed that the five natural compounds, including baicalin, Scutellarin, Hesperetin, glycyrrhizin and Nicotianamine (Figure 1) are potential compounds that target the ACE2 receptor and exert anti-virus effects for preventing 2019-nCoV infection.
Figure 1, Chemical structure of baicalin, Scutellarin, Hesperetin, glycyrrhizin and Nicotianamine.

Natural compounds candidates for 2019-nCoV treatment

In the following session, we will summarize these five natural compounds that may have therapeutic effects against 2019-nCoV infection. To generate putative binding
poses, we used the AutoDock Vina software package with the default scoring function (Trott O, Olson AJ, 2010). In the AutoDock Vina configuration files, the parameter num_modes was set to 1000 and exhaustiveness to 100. We identified the receptor-binding pocket based on the structures of ACE2 proteins. We chose all the rotatable bonds in ligands to be flexible during the docking procedure, and we kept all the protein residues inside the binding pockets rigid. We assigned the Gasteiger atomic partial charges and converted all receptors and ligands to the PDBQT format using the AutoDockTools package. We did not use explicit hydrogens either for the receptors or for the ligands.

**Baicalin**

Baicalin is extracted and purified from the Chinese medicinal plant Scutellaria baicalensis Georgi (Chinese name: Huang Qin). Baicalin has broad therapeutic effects, including anti-oxidative stress, anti-inflammation, anti-apoptosis (Chen et al., 2017; Ishfaq et al., 2019). Scientists have been shown baicalin’s antiviral activities for SARS coronavirus using the foetal rhesus kidney-4 (fRhK-4) cell line, with a EC50 12.5 ug/ml at 48 hours, and selectivity index more 4 to 8 (Chen et al., 2004). The plaque reduction assay showed that baicalin has an EC 50 of 11ug/ml (Chen et al., 2004). Those results suggest that baicalin has anti-SARS effects. Since
the 2019-nCoV shared similarity with the SARS virus, we suspect that baicalin may also show anti-virus effects on 2019-nCoV. In addition, a study showed that baicalin could inhibit ACE, with an IC50 value of 2.24 mM in vitro (Deng et al., 2012). However, whether baicalin can bind to ACE2 is not yet studied. Therefore, we use the molecular docking to test the possibility of baicalin binding to the ACE2 receptor, which may subsequently block the entry of 2019-nCoV. The docking result shows that baicalin may have strong binding to the ACE2 enzyme (Figure 2), with an estimated ΔG (kcal/mol) -8.46, and the potential binding site at ASN-149, ARG-273, HIS-505. Based on the anti-SARS activity and its potential binding to ACE2, we suggest that baicalin is one of the potential candidates for 2019-nCoV treatment. Given the low toxicity of baicalin, its efficacy on anti-2019nCoV worth further investigation.
Figure 2, molecular docking result of baicalin to ACE2 enzyme.

Scutellarin

Scutellarin is another active compound from Chinese Medicine Erigeron breviscapus (Vant.) Hand Mazz, which showed broad pharmacological effects, including anti-oxidant, anti-inflammation, vascular relaxation, anti-platelet, anti-coagulation (Wang and Ma, 2018). A study showed that scutellarin treatment could reduce the expression and activity of ACE in brain tissue *in vivo* (Wang et al., 2016). The IC50 value of scutellarin against ACE was 48.13 ± 4.98 μM (Wang et al., 2016). However, whether scutellarin could inhibit ACE2 is not yet reported. Here we conduct a molecular docking and find that scutellarin has the potential to bind to ACE2, with estimated ΔG (kcal/mol) -14.9, with binding site GLU-495, UNK-957,
ARG-482 (Figure 3). Therefore, it’s worthwhile to test whether scutellarin could inhibit ACE2 and block the infection of 2019-nCoV.

**Figure 3**, molecular docking result of Scutellarin to ACE2 enzyme.

**Hesperetin**

Hesperetin is a bioflavonoid compound abundant in Chinese Medicine citrus aurantium and Citri Reticulatae Pericarpium. Hesperetin dose-dependently inhibited cleavage activity of the 3C-like protease (3CLpro) of SARS-coronavirus in cell-free and cell-based assays, with an IC50 8.3 uM (Lin et al., 2005). Whether hesperetin could inhibit 2019-nCoV replication is not yet investigated. To
understand whether hesperetin has the potential to inhibit ACE2, we conduct the molecular docking of Hesperetin to the ACE2 enzyme, and the results showed that hesperetin has the potential binding to ACE2 with an estimated $\Delta G$ (kcal/mol) -8.3, with binding cites TYR-613, SER-611, ARG-482, GLU-479 (Figure 3). This result suggests that hesperetin may bind to ACE2, therefore, block the infection of 2019-nCoV.

**Figure 4**, molecular docking result of Hesperetin to ACE2 enzyme.

**Nicotianamine**

Nicotianamine is rich in soybean (Takenaka, 2009). Toshihiro et al. reported that nicotianamine is a potent inhibitor of ACE2, with an IC$_{50}$ value of 84 nM. The authors screened ACE2 inhibitors from various foodstuffs and found that soybean
contained vigorous ACE2 inhibitory activity. They isolated the active compound “soybean ACE2 inhibitor” (ACE2iSB), which was identical to nicotianamine by direct comparison with a standard compound. We conducted the molecular docking of Nicotianamine to the ACE2 enzyme, and the results showed that Nicotianamine has the potential biding to ACE2 with an estimated ΔG (kcal/mol) -5.1, with binding cites ARG-518, GLU-406, SER-409, GLN-522, GLN-442 (Figure 4). Since ACE2 is critical for the 2019-nCoV infection, we hypothesize that nicotianamine may block the infection of 2019-nCoV through inhibiting ACE2, which needs further investigation.

**Figure 5,** molecular docking result of Nicotianamine to ACE2 enzyme.
Glycyrrhizin

Glycyrrhizin is another plant product isolated from Chinese Medicine herb licorice root (Glycyrrhiza radix), a herb that is promising for SARS treatment (Pilcher, 2003). Glycyrrhizin is used for treating chronic hepatitis and is relatively non-toxic. *In vitro* study showed that glycyrrhizin has anti-SARS-CoV effects. It inhibited viral adsorption and penetration and was most effective when administered both during and after the viral adsorption period (Cinatl et al., 2003). The introduction of specific chemical modifications increase the antiviral potency of glycyrrhizin, but also increased the cytotoxicity, thus the selectivity index was reduced as compared with that of glycyrrhizin (selectivity index: ≥65) (Hoever et al., 2005). Whether glycyrrhizin has anti-2019-nCoV effects need further investigation. Our docking results showed that glycyrrhizin has the potential biding to ACE2 with an estimated ΔG (kcal/mol) - 9, with the binding cites ARG-559, GLN-388, ARG-393, ASP-30 (Figure 5). Given the low toxicity of glycyrrhizin, its anti-virus effects on SARS and its potential interaction with ACE2, it’s worthwhile to test its efficacy against 2019-nCoV infection.
Figure 6, molecular docking result of glycyrrhizin to ACE2 enzyme.

Summary

Drug development for treating 2019-nCoV is timely important due to its rapid expansion. Vaccine development could take a long time to complete, and its safety needs to be verified. Synthesized agents for blocking ACE2 also needs to test its toxicity. Chinese Medicine is applied for anti-virus treatment for a long time, and active compounds from Chinese Medicine may be applied for the 2019-nCoV. Due to the low toxicity and availability of some active compounds from Chinese Medicine, it is worthwhile to select potential candidates for 2019-nCoV treatment. Since 2019-nCoV share some common sequence with SARS-CoV, and used the same host receptor ACE2, we review the potential active compounds for anti-SARS-
CoV, and at the same time, predict the binding affinity of those compounds to bind
ACE2. In this study, by using the molecular docking and reviewing the literature, we
propose for the first time that baicalin, Scutellarin, Hesperetin, Nicotianamine,
glycyrrhizin has the potential to bind to ACE2 and block the entry of 2019-nCoV.
Further studies are needed to verify our results and test the anti-2019-CoV effects
of these compounds.

Notes

Dr. Hansen Chen is a Postdoctoral Fellow in Department of Neurosurgery, School
of Medicine, Stanford University.

Mr. Qiaohui Du is a Ph.D. student in School of Chinese Medicine, The University of
Hong Kong

Funding

The authors did not receive grants for this study

Acknowledgment

We thank Dr. Xingmiao Chen (From Shanghai, China) for her support and
suggestions
Conflict of interest

None

Reference

Chen, F., Chan, K., Jiang, Y., Kao, R., Lu, H., Fan, K., Cheng, V., Tsui, W., Hung, I., Lee, T., 2004. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. Journal of Clinical Virology 31(1), 69-75.

Chen, H.S., Qi, S.H., Shen, J.G., 2017. One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol 15(1), 134-156.

Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr, H.W., 2003. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361(9374), 2045-2046.

Cinatl, J., Jr., 2005. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J Med Chem 48(4), 1256-1259.

Deng, Y.F., Aluko, R.E., Jin, Q., Zhang, Y., Yuan, L.J., 2012. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm Biol 50(4), 401-406.

Hoever, G., Baltina, L., Michaelis, M., Kondratenko, R., Baltina, L., Tolstikov, G.A., Doerr, H.W., Ishfaq, M., Chen, C., Bao, J., Zhang, W., Wu, Z., Wang, J., Liu, Y., Tian, E., Hamid, S., Li, R., Ding, L., Li, J., 2019. Baicalin ameliorates oxidative stress and apoptosis by restoring mitochondrial dynamics in the spleen of chickens via the opposite modulation of NF-kappaB and Nrf2/HO-1 signaling pathway during Mycoplasma gallisepticum infection. Poult Sci 98(12), 6296-6310.

Kuhn, J.H., Radoshitzky, S.R., Li, W., Wong, S.K., Choe, H., Farzan, M., 2006. The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy, New Concepts of Antiviral Therapy. Springer, pp. 397-418.

Letko, M., & Munster, V. (2020). Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv, 2020.2001.2022.915660. doi:10.1101/2020.01.22.915660
Lin, C.W., Tsai, F.J., Tsai, C.H., Lai, C.C., Wan, L., Ho, T.Y., Hsieh, C.C., Chao, P.D., 2005. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 68(1), 36-42.

Pilcher, H., 2003. Liquorice may tackle SARS. Nature.

Shu, Y., and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data—from vision to reality. EuroSurveillance 22, PMCID: PMC5388101.

Takahashi, S., et al., Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. Biomedical Research, 2015. 36(3): p. 219-224.

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461

Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., . . . Hao, P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. SCIENCE CHINA Life Sciences(1674-7305). doi:https://doi.org/10.1007/s11427-020-1637-5

Wang, L., Ma, Q., 2018. Clinical benefits and pharmacology of scutellarin: A comprehensive review. Pharmacol Ther 190, 105-127.

Wang, W., Ma, X., Han, J., Zhou, M., Ren, H., Pan, Q., Zheng, C., Zheng, Q., 2016. Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor. PLoS One 11(1), e0146197.

Zhang, Y.Z. (2020). Initial genome release of novel coronavirus. http://virological.org/t/initial-genome-release-of-novel-coronavirus/319?from=groupmessage. Google Scholar